

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

12-1352
TAR-471

DATE: December 22, 1980

SUBJECT: EPA Registration No. 4581-341
Decco Salt #22: Caswell #311, 375A.

000471

FROM: Deloris F. Graham, FHB/TSS *D4B 1/8/81*
E 1/21/81

TO: Henry Jacoby
Product Manager (21)

Applicant: Pennwalt Corporation
Decco-Filbelt Division
P.O. Box 120
Monrovia, CA 91016

311
375A

Active Ingredients:

2,6-dichloro-4-nitroaniline.....48.8%
Thiophanate-methyl (dimethyl [1,2-phenylene]
bis(iminuocarbonothioyl)]bis(carbamate).....24.4%

Inert Ingredients.....26.8%

Background:

Resubmitted acute oral, acute dermal, eye irritation and skin irritation studies as requested in original review. An acute inhalation study was not submitted. These data are under Accession Number 243798. These studies were conducted by Applied Biological Sciences Laboratories, Glendale, California.
Alternate Method of Support.

Recommendation:

1. FHB/TSS finds the acute oral, acute dermal, eye irritation and dermal irritation studies acceptable to support the conditional registration of this product.
2. The following labeling revisions must be incorporated on label.

Label:

1. The appropriate signal word is CAUTION.
2. The statement "Keep out of lakes, streams or ponds" must be revised to read "Do not apply directly to lakes, ponds or streams."

000471

Review:

1. Acute Oral Toxicity Study: Applied Biological Sciences Laboratories, Inc.; ABSL #16557; October 14, 1980.

Procedure:

5M and 5F Sprague-Dawley rats received a 5 g/kg dose of the test material. Observations were made daily for 14 days. Necropsies were performed on all animals.

Results:

2/5 females died. Symptoms observed included lethargy, uncoordination, semicomatose and convulsions. Necropsy revealed hemorrhagic lungs, mottled congested liver, pelvic area of the kidneys was dark. It was concluded that the LD₅₀ is greater than 5 g/kg.

Study Classification: Core Guideline Data

Toxicity Category: IV-CAUTION

2. Acute Dermal Toxicity Study: Applied Biological Science Laboratories, Inc.; ABSL #16557; October 16, 1980.

Procedure:

5M and 5F New Zealand white rabbits received a 2 g/kg dose at abraded skin sites and treated areas placed under occlusive wrap for 24-hour exposure. Observations were made at the end of 24-hour exposure period and for the next two weeks. All animals were necropsied.

Results:

At 24 hours, 1/5 M died. Symptoms observed included lethargy, animals appeared dazed and immobile. All animals exhibited moderate erythema. At 72 hours, animals had flaking of the epithelial layer of the exposed skin which persisted for the remainder of the two-week period. Necropsy revealed hemorrhagic lungs and liver, darkened pelvic area of kidney and swollen testicles. It was concluded that the LD₅₀ is greater than 2 gm/kg.

Study Classification: Core Guidelines Data

Toxicity Category: III-CAUTION

2

000471

3. Eye Irritation Study: Applied Biological Sciences Laboratories, Inc.,
ABSL #16557; October 15, 1980.

Procedure:

One-tenth ml of the product was instilled in one eye of each of 9 rabbits. Six animals with treated eyes remained unwashed and three rabbits with treated eyes were washed 20-30 seconds after instillation. Observations made at 24, 48 and 72 hours and at 4 and 7 days after treatment.

Results:

No irritation observed throughout the 7 days.

Study Classification: Core Guideline Data

Toxicity Category: IV-CAUTION

4. Dermal Irritation Study: Applied Biological Sciences Laboratories; ABSL
#16557; October 14, 1980

Procedure:

6 New Zealand rabbits received 0.5 g of the test material at two intact and two abraded skin sites per animal. Treated areas were placed under occlusive wrap for 24 hour exposure period. Observations were made at 24 and 72 hours after treatment.

Results:

No irritation observed at both intact and abraded skin sites at 24 or 72 hours.

Study Classification: Core Guideline Data

Toxicity Category: IV-CAUTION

DCNA science review

Page 4 is not included in this copy.

Pages _____ through _____ are not included in this copy.

The material not included contains the following type of information:

- ☐ Identity of product inert ingredients
 - ☐ Identity of product impurities
 - ☐ Description of the product manufacturing process
 - ☐ Description of product quality control procedures
 - ☐ Identity of the source of product ingredients
 - ☐ Sales or other commercial/financial information
 - ☒ A draft product label
 - ☐ The product confidential statement of formula
 - ☐ Information about a pending registration action
 - ☐ FIFRA registration data
 - ☐ The document is a duplicate of page(s) _____
 - ☐ The document is not responsive to the request
-

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.
